Abstracts tagged "outcomes and quality of life"

Abstract Number: 1478 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Disability and Health-Related Quality of Life in Biologic-Treated Patients with Rheumatoid Arthritis in Persistent Moderate Disease Activity
Ian C. Scott^1,2, Julie Mount³, Jane Barry³ and Bruce Kirkham⁴, ¹Research Institute for Primary Care & Health Sciences, Primary Care Sciences, Keele University, Keele, United Kingdom, ²Department for Rheumatology, Haywood Hospital, Stoke on Trent, United Kingdom, ³Eli Lilly and Company, Basingstoke, United Kingdom, ⁴Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: A treat-to target (T2T) strategy is recommended for the management of rheumatoid arthritis (RA), with the target being remission or at least low disease…
Abstract Number: 2302 • 2017 ACR/ARHP Annual Meeting
The Impact of JIA on Physician and Patient-Reported Outcomes over the First Five Years Following Diagnosis
Stephanie Shoop-Worrall¹, Suzanne M Verstappen², Janet E. McDonagh³, Wendy Thomson⁴ and Kimme L. Hyrich⁴, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal and Dermatology Research, Faculty of Medicine, Biology and Health, United Kingdom, University of Manchester, Manchester, United Kingdom, ³Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁴National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Information regarding longer-term outcomes in JIA largely pre-date the introduction of biologic therapies and have been cross-sectional. The aim of this analysis was to…
Abstract Number: 961 • 2014 ACR/ARHP Annual Meeting
Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study
John G. Hanly for the Systemic Lupus International Collaborating Clinics¹, Aidan O'Keeffe², Li Su³, Murray B. Urowitz⁴, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha R Bernatsky⁸, Ann E. Clarke⁹, Daniel J. Wallace¹⁰, Joan T. Merrill¹¹, David A. Isenberg¹², Anisur Rahman¹³, Ellen M. Ginzler¹⁴, Paul Fortin¹⁵, Dafna D. Gladman⁴, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Barri Fessler²³, Kristjan Steinsson²⁴, Ola Nived²⁵, Gunnar Sturfelt²⁵, Susan Manzi²⁶, Munther A. Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Manuel Ramos-Casals³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Thomas Stoll³³, Murat Inanc³⁴, Kenneth C. Kalunian³⁵, Diane L. Kamen³⁶, Peter Maddison³⁷, Christine A. Peschken³⁸, Søren Jacobsen³⁹, Anca Askanase⁴⁰, Jill P. Buyon⁴¹, Chris Theriault⁴², Kara Thompson⁴² and Vernon Farewell³, ¹Division of Rheumatology, Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, Canada, ²MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, ³MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion, Mexico city, Mexico, ⁶Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, Canada, ⁹Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ¹⁰Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹³Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁴Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹⁵Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, ¹⁶Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁹Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²⁰Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁴Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, ²⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ²⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²⁷Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²⁹Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ³¹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³²Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³³Kantonsspital Geissbergstr, Schaffhausen, Switzerland, ³⁴Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, ³⁵UCSD School of Medicine, La Jolla, CA, ³⁶Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ³⁷Ysbyty Gwynedd Bangor, North Wales, United Kingdom, ³⁸Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴⁰Columbia University Medical Center, New York, NY, ⁴¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴²Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Improved immunosuppressive therapies have changed the treatment of lupus nephritis (LN) over the past decade. We examined the outcome of LN with current standard…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].